Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 124, Issue 1, 2012, Pages 53-58

  Rungruang, Bunja ^a   Miller, Austin ^b   Richard, Scott D ^a   Hamilton, Chad A ^c   Rodriguez, Noah ^d   Bookman, Michael A ^e   Maxwell, G Larry ^c   Krivak, Thomas C ^a   Horowitz, Neil S ^d  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e FOX CHASE CANCER CENTER   (United States)

Author keywords

FIGO staging; Lymphadenopathy; Ovarian cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; FEMALE; HUMAN; INTRAPERITONEAL CANCER; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROGNOSIS; RETROPERITONEAL CANCER; RETROSPECTIVE STUDY;

AGED; DISEASE-FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; REGRESSION ANALYSIS; RETROPERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 83055184365     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.09.024     Document Type: Article

References (25)

1. A. Jemal, R. Siegel, and J. Xu Cancer Statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. R.C. Knapp, and E.A. Friedman Aortic lymph node metastases in early ovarian cancer Am J Obstet Gynecol 119 1974 1013 1017
3. S.S. Chen Survival of ovarian carcinoma with or without lymph node metastasis Gynecol Oncol 27 1987 368 372 (Pubitemid 17158009)
4. N.M. Spirtos, G.M. Gross, and J.L. Freddo Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy Gynecol Oncol 56 1995 345 352
5. E. Burghardt, F. Giardi, and M. Lahousen Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer Gynecol Oncol 40 1991 103 106
6. FIGO Cancer Committee Staging announcement Gynecol Oncol 25 1986 383 385
7. The oncology committee of the International Federation of Gynecology and Obstetrics FIGO news: changes to the 1985 FIGO report on the result of treatment of gynaecological cancer Int J Gynecol Obstet 25 87-8 1985 1987
8. P. Benedetti-Panici, S. Greggi, and F. Maneschi Anatomical and pathological study of retroperitoneal nodes in epithelial ovarian cancer Gynecol Oncol 51 1993 150 154 (Pubitemid 24020355)
9. E. Petru, M. Lahousen, and K. Tamussino Lymphadenectomy in stage I ovarian cancer Am J Obstet Gynecol 170 1994 656 662 (Pubitemid 24089032)
10. G. Baiocchi, F. Raspagliesi, and G. Grosso Early ovarian cancer: is there a role for systematic pelvis and para-aortic lymphadenectomy? Int J Gynecol Cancer 8 1998 103 108 (Pubitemid 28246512)
11. N.F. Hacker, J.S. Berek, and L.D. Lagasse Primary cytoreductive surgery for epithelial ovarian cancer Obstet Gynecol 61 1983 413 420 (Pubitemid 13158699)
12. N. Einhorn, B. Nilsson, and K. Sjoall Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population Cancer 55 1985 2019 2025 (Pubitemid 15116964)
13. W.J. Hoskins, B.N. Bundy, and J.T. Thigpen The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study Gynecol Oncol 47 1992 159 166 (Pubitemid 23001322)
14. R. Farias-Eisner, F. Teng, and M. Oliveria The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery Gynecol Oncol 55 1994 108 110 (Pubitemid 24336128)
15. A. Lanza, F. D'addato, and M. Valli Pelvic and para-aortic lymph nodal positivity in the ovarian carcinoma: its prognostic significance Eur J Gynaecol Oncol 9 1988 36 39 (Pubitemid 18038028)
16. F. Carino, G. Fuda, and G. Ciccone Significance of lymph node sampling in epithelial carcinoma of the ovary Gynecol Oncol 65 1997 467 472 (Pubitemid 27255990)
17. T. Onda, H. Yoshikawa, and T. Yasugi Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I/II patients and superior survival to other stage III patients Cancer 83 1998 1555 1560 (Pubitemid 28465473)
18. K. Kanazawa, T. Suzuki, and M. Tokashiki The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival Gynecol Oncol 73 1999 237 241 (Pubitemid 29215737)
19. W.A. Cliby, G.D. Aletti, and T.O. Wilson Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol 103 2006 797 801 (Pubitemid 44821353)
20. G. Ferrandina, G. Scambia, and F. Legge Ovarian cancer patients with "node-positive-only" stage IIIC disease have a more favorable outcome than stage IIIA/B Gynecol Oncol 107 2007 154 156 (Pubitemid 47487441)
21. S.J. Baek, J.Y. Park, and D.Y. Kim Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer J Gynecol Oncol 19 2008 223 228
22. M.A. Bookman, M.F. Brady, and W.P. McGuire Evaluation of New platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup J Clin Oncol 27 2009 1419 1425
23. T.J. Herzog Assessing the adequacy of surgical staging for ovarian cancer Gynecol Oncol 103 2006 781 782 (Pubitemid 44821357)
24. M.A. Killackey, and A.R. Davis Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma Gynecol Oncol 51 1993 171 174 (Pubitemid 24020359)
25. J. Bell, M.F. Brady, and R.C. Young Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 102 2006 432 439 (Pubitemid 44353663)